WO1998004528A3 - Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents - Google Patents

Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents Download PDF

Info

Publication number
WO1998004528A3
WO1998004528A3 PCT/US1997/013248 US9713248W WO9804528A3 WO 1998004528 A3 WO1998004528 A3 WO 1998004528A3 US 9713248 W US9713248 W US 9713248W WO 9804528 A3 WO9804528 A3 WO 9804528A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical products
formula
pyridines
substituted
substituted pyridines
Prior art date
Application number
PCT/US1997/013248
Other languages
French (fr)
Other versions
WO1998004528A2 (en
Inventor
Gunter Schmidt
Rolf Angerbauer
Arndt Brandes
Matthias Muller-Gliemann
Hilmar Bischoff
Delf Schmidt
Stefan Wohlfeil
William R Schoen
Gaetan H Ladouceur
James H Ii Cook
Timothy G Lease
Donald J Wolanin
Richard H Kramss
Donald L Hertzog
Martin H Osterhout
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ333951A priority Critical patent/NZ333951A/en
Priority to BR9710637-2A priority patent/BR9710637A/en
Priority to IL15560697A priority patent/IL155606A0/en
Priority to CA002262434A priority patent/CA2262434A1/en
Priority to IL12825197A priority patent/IL128251A0/en
Priority to EP97936259A priority patent/EP0934274A1/en
Priority to IL15560597A priority patent/IL155605A0/en
Priority to JP50906898A priority patent/JP2001512416A/en
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to AU38971/97A priority patent/AU3897197A/en
Priority to HU0100324A priority patent/HUP0100324A3/en
Publication of WO1998004528A2 publication Critical patent/WO1998004528A2/en
Priority to NO19990399A priority patent/NO314143B1/en
Priority to BG103200A priority patent/BG103200A/en
Publication of WO1998004528A3 publication Critical patent/WO1998004528A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

Substituted pyridines of formula (IA) are produced by reaction of suitably substituted pyridylaldehydes with Grignard or Witting reagents, and the resulting products are appropriately reduced. The pyridines of formula (IA) are suitable as active compounds in pharmaceutical products, particularly in pharmaceutical products for the inhibition of cholesterol ester transfer proteins. 3-Heteroalkyl-aryl-substituted pyridines of formula (IB) are produced from pyridines which are correspondingly protected at the hydroxy group and correspondingly substituted. The compounds of formula (IB) according to the invention are suitable as active compounds in pharmaceutical products, particularly pharmaceutical products for the treatment of hyperlipoproteinemia. Substituted pyridines and benzenes of formula (IC) are produced by procedures disclosed herein, and are useful as active ingredients in pharmaceutical products, particularly pharmaceutical products for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes.
PCT/US1997/013248 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents WO1998004528A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL15560597A IL155605A0 (en) 1996-07-31 1997-07-29 Substituted pyridines as anti-hyperlipoproteinemic agents
IL15560697A IL155606A0 (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hyperglycemic agents
CA002262434A CA2262434A1 (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
IL12825197A IL128251A0 (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic anti-hyperlipoproteinemic and anti-hyperglycemic agents
EP97936259A EP0934274A1 (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
NZ333951A NZ333951A (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
JP50906898A JP2001512416A (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterolemia, anti-hyperlipoproteinemia and anti-hyperglycemic agents
BR9710637-2A BR9710637A (en) 1996-07-31 1997-07-29 Pyridines and substituted biphenyls
AU38971/97A AU3897197A (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
HU0100324A HUP0100324A3 (en) 1996-07-31 1997-07-29 Substituted pyridine and biphenyl derivatives as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents, process for producing them and pharmaceutical compositions containing them
NO19990399A NO314143B1 (en) 1996-07-31 1999-01-28 Substituted pyridines and biphenyls, methods of preparation, pharmaceutical products containing them and the use of pharmaceutical preparations
BG103200A BG103200A (en) 1996-07-31 1999-02-23 Substituted pyridines and biphenyls as antihypercholesterinemic, antihyperlipoproteinemic and antihyperglycemic formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69011196A 1996-07-31 1996-07-31
US08/690,111 1996-07-31

Publications (2)

Publication Number Publication Date
WO1998004528A2 WO1998004528A2 (en) 1998-02-05
WO1998004528A3 true WO1998004528A3 (en) 1999-11-11

Family

ID=24771137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013248 WO1998004528A2 (en) 1996-07-31 1997-07-29 Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents

Country Status (24)

Country Link
US (1) US6218431B1 (en)
EP (1) EP0934274A1 (en)
JP (1) JP2001512416A (en)
KR (1) KR20000029723A (en)
CN (1) CN1239474A (en)
AR (2) AR008789A1 (en)
AU (1) AU3897197A (en)
BG (1) BG103200A (en)
BR (1) BR9710637A (en)
CA (1) CA2262434A1 (en)
CO (1) CO4900061A1 (en)
CZ (1) CZ30899A3 (en)
HR (1) HRP970425A2 (en)
HU (1) HUP0100324A3 (en)
ID (1) ID19422A (en)
IL (1) IL128251A0 (en)
NO (1) NO314143B1 (en)
NZ (1) NZ333951A (en)
PL (1) PL333465A1 (en)
RU (1) RU2195443C2 (en)
TR (3) TR199902326T2 (en)
TW (1) TW520360B (en)
WO (1) WO1998004528A2 (en)
ZA (1) ZA976730B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
ES2436610T3 (en) 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CZ303639B6 (en) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-oxide of 4-phenyl pyridine derivative, process for its preparation and medicament in which the derivative is comprised
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
JP2004513935A (en) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ Glucagon antagonist / inverse agonist
MXPA03010612A (en) 2001-05-22 2004-04-02 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues.
EP1935885A3 (en) * 2001-05-22 2008-10-15 Neurogen Corporation Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
JP2004534812A (en) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition of dispersion of drug and neutral polymer
MXPA03010165A (en) 2001-06-22 2004-03-10 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6740776B2 (en) 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
CN1596240A (en) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 Chalcone derivatives and their use to treat diseases
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038375A1 (en) 2002-02-01 2005-01-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO
DK1533292T3 (en) 2002-08-30 2007-06-04 Japan Tobacco Inc Dibenzylamine compound and its medical use
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040209928A1 (en) * 2002-12-30 2004-10-21 Ravi Kurukulasuriya Glucagon receptor antagonists/inverse agonists
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20070066590A1 (en) * 2003-02-24 2007-03-22 Jones Robert M Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
BRPI0408442A (en) 2003-03-17 2006-04-04 Japan Tobacco Inc method for increasing the oral bioavailability of s- [2 - ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanothioate
JP5546715B2 (en) 2003-03-17 2014-07-09 日本たばこ産業株式会社 CETP inhibitor pharmaceutical composition
WO2004103310A2 (en) * 2003-05-20 2004-12-02 New England Medical Center Hospitals, Inc. Methods and compositions for the treatment of metabolic disorders
AR045047A1 (en) * 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
CL2004001884A1 (en) 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
PE20050444A1 (en) * 2003-10-31 2005-08-09 Takeda Pharmaceutical PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS
AU2004312001B2 (en) * 2003-12-19 2009-08-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
CA2548374C (en) 2003-12-23 2014-05-27 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
PL1756064T3 (en) * 2004-06-04 2008-11-28 Merck Sharp & Dohme Pyrazole derivatives, compositions containing such compounds and methods of use
DE602005011279D1 (en) * 2004-06-04 2009-01-08 Arena Pharm Inc SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES
WO2006017055A2 (en) * 2004-07-07 2006-02-16 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
CA2574147A1 (en) * 2004-07-22 2006-02-09 Linda Brockunier Substituted pyrazoles, compositions containing such compounds and methods of use
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
PT1853266E (en) 2005-01-10 2012-01-20 Cortendo Ab Publ 2s,4r ketoconazole for treating diabetes, metabolic syndrome and other conditions
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
PL1931350T5 (en) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
RS20080112A (en) * 2005-09-16 2009-05-06 Arena Pharmaceuticals Inc., Modulators of metabolism and the treatment of disorders related thereto
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
JP5198280B2 (en) * 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー Glucagon receptor antagonists and their preparation and therapeutic use
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
AU2006330072B2 (en) * 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
DE102006012548A1 (en) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituted chromanol derivatives and their use
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009537525A (en) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2076265A4 (en) 2006-10-02 2010-09-22 Cortendo Invest Ab Ketoconazole enantiomer in humans
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170059B1 (en) * 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
US8293721B2 (en) * 2007-06-20 2012-10-23 Merck Sharpe & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
JP2010530416A (en) * 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション CETP inhibitors derived from benzoxazole arylamides
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2464228B1 (en) 2009-08-13 2017-12-06 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2011028455A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2501685A1 (en) 2009-11-16 2012-09-26 Mellitech [1,5]-diazocin derivatives
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2787360C (en) 2010-02-03 2019-03-05 Takeda Pharmaceutical Company Limited Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2693882B1 (en) 2011-04-08 2017-06-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP2014518890A (en) 2011-06-02 2014-08-07 インターベット インターナショナル ベー． フェー． Imidazole derivatives
CA2838079A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
MX2014001849A (en) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors.
CN103958511A (en) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
WO2013048916A1 (en) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2013155600A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
KR20150046056A (en) * 2012-08-24 2015-04-29 에프. 호프만-라 로슈 아게 New bicyclicpyridine derivatives
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
CN106456998B (en) 2014-04-17 2020-07-28 默沙东公司 Sitagliptin tannate complex
JP6578349B2 (en) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション Cytochrome P450 inhibitors and uses thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
BR112017008160A8 (en) 2014-10-24 2023-04-11 Merck Sharp & Dohme PEPTIDE, COMPOSITION, METHODS FOR TREATMENT OF A PATIENT OR INDIVIDUAL AND FOR TREATMENT OF A METABOLIC DISEASE, AND, USES OF A PEPTIDE AND A COMPOSITION
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
KR20240042548A (en) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
ES2929526T3 (en) 2015-06-22 2022-11-29 Arena Pharm Inc (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
WO2017062334A1 (en) 2015-10-05 2017-04-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
MA53353A (en) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3029857C (en) * 2016-07-05 2023-07-04 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018034918A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
MA47504A (en) 2017-02-16 2019-12-25 Arena Pharm Inc COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
CN108558847A (en) * 2018-05-31 2018-09-21 马文军 A kind of ester derivative and its application in preventing cardiovascular and cerebrovascular disease
CN108484573B (en) * 2018-06-26 2019-10-29 王先化 A kind of indole derivatives and its application in diabetes
CN110833550B (en) * 2018-08-15 2023-03-24 广西梧州制药（集团）股份有限公司 Application of pyrazolopyrimidine derivative in treatment of liver injury caused by acute pancreatitis
WO2020074958A1 (en) 2018-10-12 2020-04-16 Strongbridge Dublin Limited Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
CN116077492B (en) * 2023-02-07 2024-03-15 华中科技大学协和深圳医院 Application of glucagon receptor antagonist-3 in preparation of medicine for resisting gram positive bacterial infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306929A2 (en) * 1987-09-08 1989-03-15 Warner-Lambert Company 6-[[(Substituted)pyridin-3-YL]alkyl]-and alkenyl]-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0325129A2 (en) * 1988-01-20 1989-07-26 Bayer Ag Disubstituted pyridines
EP0325130A2 (en) * 1988-01-20 1989-07-26 Bayer Ag Substituted pyridines
EP0444533A2 (en) * 1990-02-26 1991-09-04 E.R. SQUIBB & SONS, INC. Quinoline and pyridine anchors for HMG-CoA reductase inhibitors
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
EP0603699A1 (en) * 1992-12-24 1994-06-29 Bayer Ag Substituted pyridines as HMG-CoA reductase inhibitors
EP0742208A1 (en) * 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
EP0796846A1 (en) * 1996-03-20 1997-09-24 Bayer Ag 2-Aryl substituted pyridines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES535014A0 (en) 1983-08-11 1985-08-01 Monsanto Co A PROCEDURE FOR PREPARING SUBSTITUTED PIRIDINE DERIVATIVES IN POSITIONS 2 AND 6
US4698093A (en) 1984-11-06 1987-10-06 Monsanto Company Herbicidal (2 or 6)-fluoroalkyl-4-amino pyridine derivatives
US4655816A (en) 1984-11-06 1987-04-07 Monsanto Company Herbicidal 2-trifluoromethyl 3-pyridine carboxylic acid derivatives
JPH0778059B2 (en) 1986-03-11 1995-08-23 ダイセル化学工業株式会社 Pyrone-3-carboxamide derivative and herbicide
NO881411L (en) 1987-04-14 1988-10-17 Bayer Ag SUBSTITUTED PYROLES.
DE3817808A1 (en) 1987-07-21 1989-02-02 Bayer Ag METHOD FOR PRODUCING 2-SUBSTITUTED PYRROL
US4997837A (en) 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO890521L (en) 1988-02-25 1989-08-28 Bayer Ag SUBSTITUTED PYRIMIDINES.
DD283612A5 (en) 1988-02-25 1990-10-17 Bayer Aktiengesellschaft,De PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLINONES AND IMIDAZOLINTHIONES
NO890522L (en) 1988-02-25 1989-08-28 Bayer Ag SUBSTITUTED IMIDAZOLINONES AND IMIDAZOLINTHIONES.
NO890988L (en) 1988-03-24 1989-09-25 Bayer Ag DISUBSTITUTED PYROLES.
EP0339342A1 (en) 1988-04-23 1989-11-02 Bayer Ag N-substituted N-amino pyrroles
EP0352575A3 (en) 1988-07-28 1991-08-21 Bayer Ag Substituted annealed pyrroles
US5164506A (en) 1988-12-14 1992-11-17 Bayer Aktiengesellschaft Substituted 2-pyridones and pyrid-2-thiones compounds
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
AU618158B2 (en) 1989-01-07 1991-12-12 Bayer Aktiengesellschaft New substituted pyrido(2,3-d)pyrimidines
DE3905908A1 (en) 1989-02-25 1990-09-06 Bayer Ag Substituted quinolines, process for their preparation, and their use in medicaments
DE3909378A1 (en) 1989-03-22 1990-09-27 Bayer Ag SUBSTITUTED BIPHENYLE
DE3911064A1 (en) 1989-04-06 1990-10-11 Bayer Ag SUBSTITUTED 1,8-NAPHTHYRIDINE
US5145959A (en) 1989-07-18 1992-09-08 Bayer Aktiengesellschaft Substituted pyrido (2,3-d) pyrimidines as intermediates
US5183897A (en) 1989-08-03 1993-02-02 Bayer Aktiengesellschaft Certain intermediate imino-substituted pyridines
US5072023A (en) 1990-02-15 1991-12-10 E. R. Squibb & Sons, Inc. Process for preparing highly substituted phenyls
DE4022414A1 (en) 1990-07-13 1992-01-16 Bayer Ag SUBSTITUTED PYRROLO-PYRIDINE
DE4023308A1 (en) 1990-07-21 1992-01-23 Bayer Ag SUBSTITUTED PYRIDO OXAZINE

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306929A2 (en) * 1987-09-08 1989-03-15 Warner-Lambert Company 6-[[(Substituted)pyridin-3-YL]alkyl]-and alkenyl]-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0325129A2 (en) * 1988-01-20 1989-07-26 Bayer Ag Disubstituted pyridines
EP0325130A2 (en) * 1988-01-20 1989-07-26 Bayer Ag Substituted pyridines
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
EP0444533A2 (en) * 1990-02-26 1991-09-04 E.R. SQUIBB & SONS, INC. Quinoline and pyridine anchors for HMG-CoA reductase inhibitors
EP0603699A1 (en) * 1992-12-24 1994-06-29 Bayer Ag Substituted pyridines as HMG-CoA reductase inhibitors
EP0742208A1 (en) * 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
EP0796846A1 (en) * 1996-03-20 1997-09-24 Bayer Ag 2-Aryl substituted pyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. A. ROBL ET AL.: "Phosphorus-Containing Inhibitors of HMG-CoA Reductase. 2. Synthesis and Biological Activities of a Series of Substituted Pyridines Containing a Hydroxyphosphinyl Moiety", J. MED. CHEM., vol. 34, no. 9, 1991, pages 2804 - 2815, XP002045951 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Also Published As

Publication number Publication date
HRP970425A2 (en) 1998-08-31
HUP0100324A3 (en) 2001-06-28
CN1239474A (en) 1999-12-22
TR199902325T2 (en) 2000-02-21
IL128251A0 (en) 1999-11-30
ZA976730B (en) 1999-07-29
EP0934274A1 (en) 1999-08-11
KR20000029723A (en) 2000-05-25
AR037300A2 (en) 2004-11-03
BR9710637A (en) 2000-10-31
NZ333951A (en) 2000-09-29
TR199902326T2 (en) 2000-05-22
NO314143B1 (en) 2003-02-03
WO1998004528A2 (en) 1998-02-05
NO990399D0 (en) 1999-01-28
AU3897197A (en) 1998-02-20
PL333465A1 (en) 1999-12-20
CZ30899A3 (en) 1999-05-12
BG103200A (en) 1999-11-30
NO990399L (en) 1999-03-29
CO4900061A1 (en) 2000-03-27
ID19422A (en) 1998-07-09
CA2262434A1 (en) 1998-02-05
HUP0100324A2 (en) 2001-05-28
AR008789A1 (en) 2000-02-23
US6218431B1 (en) 2001-04-17
TR199900163T2 (en) 1999-04-21
TW520360B (en) 2003-02-11
JP2001512416A (en) 2001-08-21
RU2195443C2 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO1998004528A3 (en) Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
PL352367A1 (en) Glucagon antagonists/inverse agonists
WO2004005286A3 (en) Viral inhibitors
CA2356158A1 (en) Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
IL108520A (en) 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BG101209A (en) Hypolipidemic compounds
PL326203A1 (en) (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors
AU3285499A (en) Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
HUP0102425A3 (en) Imidazo pyridine derivatives which inhibit gastric acid secretion, process for producing them and pharmaceutical compositions containing them
AU7603000A (en) Systems for delivering anti-infective compositions from frangible ampules to treat disordered tissue such as cold sores
AU3756800A (en) Display system for advancing products
WO2003059291A3 (en) Treatment of bone disorders with skeletal anabolic drugs
AU2003219331A8 (en) (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
WO1998045259A3 (en) Polyaromatic antiviral compositions
WO2000000198A8 (en) Piperidine derivatives having effects on serotonin related systems
CA2430488A1 (en) Detection of microbial metabolites
ZA966576B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them.
AU5982298A (en) Process for the preparation of 2-{{(2-pyridinyl)me thyl}sulfinyl}-1h-benzimidazoles and novel compounds of use for such purpos
ZA995597B (en) Process for the preparation of nicotinic acid.
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
AU5982198A (en) Process for the preparation of 2-{{(2-pyridinyl)me thyl}sulfinyl}-1h-benzimidazoles and novel compounds of use for such purpos
AU4026797A (en) Process for the preparation of contrast agents
AU8370498A (en) Novel pyrimidin derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198258.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997936259

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2262434

Country of ref document: CA

Ref document number: 2262434

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/001062

Country of ref document: MX

Ref document number: 333951

Country of ref document: NZ

Ref document number: PV1999-308

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1999/00163

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1019997000826

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 509068

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-98/99

Country of ref document: YU

WWP Wipo information: published in national office

Ref document number: PV1999-308

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997936259

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999/02326

Country of ref document: TR

Ref document number: 1999/02325

Country of ref document: TR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1019997000826

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 155606

Country of ref document: IL

Ref document number: 155605

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: PV1999-308

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019997000826

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997936259

Country of ref document: EP